预计2025年实现归属于上市公司股东的净利润约人民币2.33亿元到人民币3.49亿元，与上年同期的数据 相比，将增加约人民币15,853.52万元到人民币 27,484.06万元，同比增加约214.0%到371.0%。 预计 2025 年实现归属于上市公司股东的扣除非经常性损益的净利润约人民币 24,638.00 万元到人民币 36,956.99 万元，与上年同期的数据相比，将增加约人民币 22,280.66 万元到人民币 34,599.65 万元，同 比增加约945.2%到1,467.7%。 格隆汇1月20日丨昭衍新药(603127.SH)公布，预计2025年实现营业收入约人民币15.73亿元到人民币 17.38亿元，与上年同期的数据相比，将减少约人民币28,019.80 万元到人民币 44,573.47 万元，同比减少 约 13.9%到 22.1%。 ...

Core Viewpoint - Zhaoyan New Drug (603127.SH) forecasts a net profit attributable to shareholders of 233 million to 349 million yuan for the fiscal year 2025, representing a year-on-year growth of 214.0% to 371.0% [1] Group 1 - The increase in profit is driven by rising market prices of biological assets and natural growth appreciation, leading to positive fair value changes [1]

Core Viewpoint - Zhaoyan New Drug (603127) expects a net profit attributable to shareholders of approximately 233 million to 349 million yuan in 2025, representing a year-on-year increase of about 214% to 371% [1] Group 1 - The increase in net profit is driven by the rise in market prices of biological assets and the natural growth appreciation of the assets [1] - The dual factors of market price increase and asset appreciation contribute positively to the company's performance [1]

Core Viewpoint - Zhaoyan New Drug has released its annual performance forecast, expecting a significant increase in net profit for 2025, driven by rising market prices of biological assets and stable laboratory operations [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 232.61 million to 348.92 million yuan for 2025, representing a year-on-year increase of 214.00% to 371.00% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be around 246.38 million to 369.57 million yuan, with a year-on-year growth of 945.20% to 1,467.70% [1] Group 2: Contributing Factors - The increase in fair value of biological assets is attributed to both rising market prices and natural growth, positively impacting the company's performance [1] - Despite maintaining stable operations in the laboratory, the company experienced a decline in revenue and gross margin from performance contracts due to previous intense industry competition, leading to a decrease in profit contribution from laboratory services [1]

Core Viewpoint - The company expects a significant increase in net profit attributable to shareholders for 2025, projecting between RMB 233 million and RMB 349 million, which represents a year-on-year increase of approximately 214.0% to 371.0% compared to the previous year [1] Financial Performance - The projected net profit increase is expected to be between RMB 159 million and RMB 275 million compared to the same period last year [1] - The growth in fair value is driven by a combination of rising market prices for biological assets and natural growth appreciation [1]

Group 1 - On January 16, Zhaoyan New Drug experienced a decline of 1.84% with a trading volume of 673 million yuan, and the net financing buy was -7.46 million yuan [1] - As of January 16, the total balance of margin trading for Zhaoyan New Drug was 420 million yuan, with a financing balance of 415 million yuan, accounting for 1.56% of the circulating market value, which is below the 50th percentile level over the past year [1] - The company primarily engages in non-clinical safety evaluation services for drugs, with 95.59% of its main business revenue derived from non-clinical research services [1] Group 2 - As of September 30, the number of shareholders for Zhaoyan New Drug increased by 57.61% to 96,500, while the average circulating shares per person remained at 0 [2] - For the period from January to September 2025, Zhaoyan New Drug reported an operating income of 985 million yuan, a year-on-year decrease of 26.23%, while the net profit attributable to the parent company was 80.71 million yuan, reflecting a year-on-year increase of 214.79% [2] - The company has distributed a total of 703 million yuan in dividends since its A-share listing, with 356 million yuan distributed over the past three years [3]

（文章来源：证券日报） 证券日报网讯 1月13日，昭衍新药在互动平台回答投资者提问时表示，公司非人灵长类模型主要是自 用，用于非临床安评实验相关研究，不涉及脑机接口业务，相关信息请以公司披露的相关公告为准。 ...

格隆汇1月13日丨昭衍新药(603127.SH)在互动平台表示，公司非人灵长类模型主要是自用，用于非临床 安评实验相关研究，不涉及脑机接口业务。 ...

格隆汇1月13日丨昭衍新药(603127.SH)在互动平台表示，公司非人灵长类模型主要是自用，用于非临床 安评实验相关研究，不涉及脑机接口业务。 ...

1月13日，昭衍新药涨5.1%，截至发稿，报42.44元/股，成交5.77亿元，换手率2.19%，总市值318.02亿 元。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，融通基金旗下1只基金重仓昭衍新药。融通医疗保健行业混合A/B（161616）三季度减持 31.85万股，持有股数93.83万股，占基金净值比例为3.95%，位居第六大重仓股。根据测算，今日浮盈 赚取约193.3万元。 融通医疗保健行业混合A/B（161616）成立日期2012年7月26日，最新规模7.08亿。今年以来收益 8.55%，同类排名1381/8836；近一年收益22.93%，同类排名5278/8091；成立以来收益143.83%。 融通医疗保健行业混合A/B（161616）基金经理为万民远、刘曦阳。 截至发稿，万民远累计任职时间9年143天，现任基金资产总规模59.57亿元，任职期间最佳基金回报 149.74%， 任职期间最差基金回报-19.05%。 刘曦阳累计 ...